Summary
This 8-K filing from McKesson Corporation (MCK), dated April 12, 2012, primarily serves to announce an update regarding the company's prime pharmaceutical supplier relationship with the Department of Veterans Affairs (VA). The update was provided via a press release on April 11, 2012, and is attached as an exhibit to this filing. For investors, this announcement is significant as it relates to a key customer relationship. A strong, ongoing relationship with a major government entity like the VA can indicate stable revenue streams and demonstrate the company's capabilities in fulfilling large-scale pharmaceutical supply contracts. While the 8-K itself does not detail the specifics of the update, the filing directs investors to the press release for further information on the status and implications of this important partnership.
Key Highlights
- 1McKesson Corporation (MCK) filed an 8-K on April 12, 2012.
- 2The filing's primary purpose is to report an update on the company's relationship with the Department of Veterans Affairs (VA).
- 3McKesson is a prime pharmaceutical supplier to the VA.
- 4An update regarding this key supplier relationship was communicated via a press release on April 11, 2012.
- 5The press release is attached as Exhibit 99.1 to the 8-K filing.
- 6This filing does not contain specific financial results or operational metrics, but points to the press release for details.